Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.

Liver Transpl Surg

Department of Anesthesiology, Mayo Foundation, Rochester, MN 55905, USA.

Published: September 1999

Patients with end-stage liver failure, portal hypertension, and associated pulmonary artery hypertension (portopulmonary hypertension [PPHTN]) have a high mortality when undergoing liver transplantation. Successful transplantation in these patients may depend on efforts to reduce pulmonary artery pressure (PAP). To this end, a number of centers are using a continuous intravenous (IV) infusion of epoprostenol, which has been shown to improve symptoms, extend life span, and reduce PAP in patients with primary pulmonary hypertension. We report four cases in which treatment of patients with PPHTN with continuous IV epoprostenol was followed by the development of progressive splenomegaly, with worsening thrombocytopenia and leukopenia. This finding may limit the usefulness of epoprostenol in PPHTN and influence the timing of transplantation in such patients.

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.500050517DOI Listing

Publication Analysis

Top Keywords

progressive splenomegaly
8
portopulmonary hypertension
8
pulmonary artery
8
transplantation patients
8
hypertension
5
patients
5
epoprostenol
4
splenomegaly epoprostenol
4
epoprostenol therapy
4
therapy portopulmonary
4

Similar Publications

: Accurate and reproducible spleen volume measurements are essential for assessing treatment response and disease progression in myelofibrosis. This study evaluates techniques for measuring spleen volume on abdominal MRI. : In 20 patients with bone marrow biopsy-proven myelofibrosis, 5 observers independently measured spleen volume on 3 abdominal MRI pulse sequences, 3D-spoiled gradient echo T1, axial single-shot fast spin echo (SSFSE) T2, and coronal SSFSE T2, using ellipsoidal approximation, manual contouring, and 3D nnU-Net model-assisted contouring comparing coefficients of variation.

View Article and Find Full Text PDF

Primary splenic involvement in kaposiform lymphangiomatosis: A case report.

Int J Surg Case Rep

January 2025

University of South Carolina School of Medicine Greenville, 607 Grove Rd, Greenville, SC 29605, United States of America; Prisma Health Department of Surgery, 701 Grove Rd, 3rd floor Support Tower, Greenville, SC 29605, United States of America. Electronic address:

Introduction: Kaposiform Lymphangiomatosis (KLA) is a rare, pathologically distinct lymphatic anomaly characterized by abnormal lymphatic channel malformation and a high mortality rate. Previous studies describe primary thoracic involvement.

Presentation Of Case: A previously healthy eighteen-month-old female presented to the pediatric emergency department with sudden onset of petechiae and bruising.

View Article and Find Full Text PDF

Introduction: Glycerol-3-phosphate dehydrogenase 1 (GPD1) deficiency is an autosomal recessive disorder causing hypertriglyceridemia, hepatomegaly, fatty liver, and hepatic fibrosis in infancy. It is an under-recognized cause of pediatric steatotic liver disease (SLD) with only 36 cases reported worldwide.

Method: We analyzed the clinical profile of our five cases diagnosed by exome sequencing (ES) and reviewed the published cases till December 2023 using PubMed search.

View Article and Find Full Text PDF

Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by progressive bone marrow fibrosis and splenomegaly. Ruxolitinib is the standard-of-care first-line treatment option for MF. This review summarizes real-world effectiveness and safety of ruxolitinib in more than 4500 patients with MF from real-world settings, including expanded-access and phase 4 trials, as well as registry, postmarketing, and retrospective studies in the 10 years since regulatory approval.

View Article and Find Full Text PDF

Background: Mucopolysaccharidosis type I (MPS I - IDUA gene) is a rare autosomal recessive lysosomal storage disorder. Clinical symptoms, including visceral overload, are progressive and typically begin postnatally. Descriptions of hepatosplenomegaly associated with lysosomal pathology are uncommon during the prenatal period.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!